Humacyte posts bigger-than-expected Q4 loss

Humacyte

27/03/2026 11:13

Overview

US bioengineered tissue maker's Q4 net income and operating income missed analyst expectations

Company reported $0.5 mln Q4 revenue, driven by Symvess sales and research collaborations

Company received $1.475 mln purchase commitment for Symvess clinical evaluation in Saudi Arabia

Outlook

Company expects top-line interim results from V012 Phase 3 hemodialysis study by early June 2026

Humacyte plans to submit supplemental BLA for ATEV hemodialysis indication in second half of 2026

Company aims to begin first-in-human trial for coronary tissue engineered vessel in second half of 2026

Result Drivers

US LAUNCH - Co said Q4 sales were driven by commercial launch of Symvess in US and growing awareness among surgeons

INTERNATIONAL INTEREST - $1.475 mln purchase commitment for Symvess clinical evaluation and outreach in Saudi Arabia highlighted international demand

INVENTORY RESERVE - Co recorded $8.9 mln inventory reserve due to lack of consistent sales history, impacting cost of goods sold and net loss

Company press release: ID:nGNX5PsycG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$24.80 mln
-$23.30 mln (5 Analysts)
Q4 Operating Income
Miss
-$30.84 mln
-$22.78 mln (5 Analysts)
Q4 Basic EPS
-$0.13
Q4 Operating Expenses
$31.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Humacyte Inc is $3.50, about 349.6% above its March 26 closing price of $0.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)